Thirty drugs intended to fight once morest pathologies (cancer, diabetes, cardiovascular diseases, etc.) considered to be priorities, available in forty countries under a single brand and sold “without any profit”. It is the promise of the new “Impact” program announced on July 4 by the French laboratory Sanofi. The initiative comes from Sanofi Global Health (SGH), a branch of the company created in April 2021 with the aim of reaching new patients, including in developing countries.
To read
“Africa is not self-sufficient for any vaccine or medicine”
This launch, explains Jon Fairest, the head of SGH, aims to “ensure the mise making our medicines available to the poorest populations on the planet and helping them to have access to sustainable, quality health care. The Impact brand is non-profit: we seek the best possible price, with smaller margins. But unlike others we sell, we don’t give. »
